(Q36985933)

17 August 2017

1 reference

title

Current state and future directions of neurochemical biomarkers for Alzheimer's disease (English)

1 reference

17 August 2017

0 references

0 references

Daniëlle de Jong

1

1 reference

PubMed ID

17970699

17 August 2017

Berry P H Kremer

series ordinal

2

1 reference

PubMed ID

17970699

17 August 2017

Marcel G M Olde Rikkert

series ordinal

3

1 reference

PubMed ID

17970699

17 August 2017

Marcel M Verbeek

series ordinal

4

1 reference

17 August 2017

1 January 2007

1 reference

Clinical Chemistry and Laboratory Medicine

17 August 2017

1 reference

17 August 2017

45

1 reference

17 August 2017

11

1 reference

17 August 2017

1421-1434

1 reference

The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease

17 August 2017

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tau missing from CSF: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid tau levels in frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Different variants of frontotemporal dementia: a neuropathological and immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal protein tau is elevated in early Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Analysis of the human lumbar cerebrospinal fluid proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Towards a high resolution separation of human cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Proteome studies of CSF in AD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Proteome-based plasma biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Identification of potential CSF biomarkers in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Lipid peroxidation in aging brain and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Soluble adhesion molecules and angiotensin-converting enzyme in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Neurofilament protein synthesis and phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Haplotypes extending across ACE are associated with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Plasma Abeta levels do not reflect brain Abeta levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Evidence based diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Comparative accuracy: assessing new tests against existing diagnostic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

Tau Protein in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2007.320

21 January 2018

Identifiers

DOI

10.1515/CCLM.2007.320

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hud7x2g4bnbnbmynqsogbmqc5e

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_hud7x2g4bnbnbmynqsogbmqc5e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hud7x2g4bnbnbmynqsogbmqc5e

mapped directly with Wikidata item

30 July 2022

based on heuristic

1 reference

https://api.fatcat.wiki/v0/release/hud7x2g4bnbnbmynqsogbmqc5e